亚新网站亚新网站

0571-87968248 CHINESE
  • Home
  • About us
    ProfileCultureHistory
  • News
    Company newsTrade showsIndustry news
  • Products
    COVID-19 IgG/IgM Rapid Test KitAllergen-specific IgE antibodies test kit seriesFood-specific IgG/IgG4 antibodies test seriesSingle/Polynomial allergen test seriesSingle allergen component test seriesGenetic test for allergic diseases series productsOther seriesProduct specific equipment
  • About allergies
    Scientific literaturePopular scienceVideos
  • Contact us
    Join usContact us
Scientific literaturePopular scienceVideos
Components literatureGene literatureMechanism literatureProbioticsTest literatureDesensitizationOther

Release date:2019-06-26

JACI
[IF:13.258]
Fast generation of IgE, IgG cloning sharing the same variable region to 1 and IgG4 by PIPE the major birch pollen allergen Bet v 1  
DOI: org/10.1016/j.jaci.2018.12.571
Abstract: 
RATIONALE: Birch pollen allergy with the single major allergen Bet v 1 is a paradigm to study the molecular interplay of IgE and IgG1 or IgG4 in sensitization and allergen immunotherapy. However, there is a lack in the availability of such antibodies. We here aimed to fuel our antibody PIPEline by using Polymerase Incomplete Primer Extension (PIPE) cloning (Ilieva et al., 2017), the latest method for fast creation of different classes of antibodies sharing the same variable region.
METHODS: Variable region sequences from the literature (Levin et al.,2014) were used to create vectors coding for IgE, IgG1 and IgG4 via PIPE cloning. These self-assembled plasmids were then expressed in the Expi293F system at a cell culture volume of 30 ml. Recombinant antibodies were purified via affinity chromatography and integrity tested in SDS-PAGE. Concentration was determined via BCA protein assay.Specificity to Bet v 1 was determined by dot blot and ISAC112 microarray.
RESULTS: Expression of all three antibody classes in Expi293F cells resulted in high yields from 0.9 mg (IgE) to 6 and 4.4 mg (IgG1 and IgG4,respectively). PIPE cloning delivered correctly assembled IgE, IgG1 and IgG4 antibodies specifically recognizing Bet v 1.
CONCLUSIONS: PIPE cloning proves to be a highly efficient method for the production of recombinant antibodies against Bet v 1. As these antibodies belong to different classes but share the same variable region they will be useful tools for researching mechanisms underlying type 1 allergy as well as allergen immunotherapy.
First Author:
Jill A. Poole  
Correspondence:
Nebraska Medical Center, Omaha, NE 68198.
All Authors:
Jill A. Poole, Charles S. Barnes, Jeffrey G. Demain, Jonathan A. Bernstein, Mahesh A. Padukudru,  William J. Sheehan, Guillermo Guidos Fogelbach, James Wedner, Rosa Codina, Estelle Levetin, John R. Cohn, Steve Kagen, Jay M. Portnoy, Andre E.
2019-05-08  Article
  • Home
  • About us
  • News
  • Products
  • About allergies
  • Contact us
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd.  Copyright    HZKC Technical support   浙ICP备14005341号   (浙)-非经营性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist.      Tel: 0571-87968248-805     Website:www.therealkc.com

COPYRIGHT©2003-2025  www.therealkc.com CORPORATION. ALL RIGHTS RESERVED

Official WeChat

开云手机登录入口 | 星空体育·(StarSky Sports)官方网站 | 云博app官方在线入口 | 江南平台 | 江南登录网站 | 开云官方注册 | 乐鱼在线登录最新官网(中国)官方有限公司 | 华球平台 | 开云网页版 |